HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany-Reference-Cited by-同舟云学术

HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany

Published:2019-03-02 Issue:5 Volume:474 Page:551-560
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Baretton Gustavo, ,Kreipe Hans H.,Schirmacher Peter,Gaiser Timo,Hofheinz Ralf,Berghäuser Karl-Heinz,Koch Winfried,Künzel Claudia,Morris Stefanie,Rüschoff Josef

Funder

Roche Pharma AG, Grenzach-Wyhlen, Germany

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-019-02541-9.pdf

Reference26 articles.

1. Boku N (2014) HER2-positive gastric cancer. Gastric Cancer 17:1–12. https://doi.org/10.1007/s10120-013-0252-z

2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X

3. Van Cutsem E, Bang Y, Feng-yi F et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476–484. https://doi.org/10.1007/s10120-014-0402-y

4. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB III, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446–464. https://doi.org/10.1200/JCO.2016.69.4836

5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726. https://doi.org/10.1200/JCO.2002.20.3.719

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer;Frontiers in Oncology;2024-06-14

2. Deep learning model based on multi-lesion and time series CT images for predicting the benefits from anti-HER2 targeted therapy in stage IV gastric cancer;Insights into Imaging;2024-02-27

3. Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target;Cancers;2023-10-27

4. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321);Frontiers in Oncology;2023-10-16

5. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade;Journal for ImmunoTherapy of Cancer;2023-06